Moderate to severe plaque psoriasis has traditionally been treated with agents that have toxicities associated with long-term use. Many patients therefore cannot be treated safely, conveniently or effectively with traditional therapies. Recent phase 3 clinical trials for efalizumab, a biological agent targeted specifically at the T-cell-based pathology of psoriasis, have demonstrated its short- and long-term efficacy and safety for the treatment of psoriasis. This article reviews results from 12-week, six-month, and three-year trials, focusing on the drug's safety, efficacy, and therapeutic response time, as well as the phenomenon of rebound in non-responding patients. Efalizumab emerges as an important addition to the dermatological pharmacopeia for the long-term treatment of psoriasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10227-006-0102-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psoriasis in People With Skin of Color: An Evidence-Based Update.
Int J Dermatol
January 2025
Department of Dermatology, Ain Shams University, Cairo, Egypt.
Variations in epidemiology, pathophysiology, genetics, clinical presentation, management, quality of life (QoL) impact, and access to care and research exist globally across the spectrum of individuals with psoriasis. This article aims to provide an evidence-based update on the characteristics of psoriasis in individuals with skin of color (SOC), a population in which psoriasis data have historically been limited. A literature search was conducted from January 2018 until August 2023 in Pubmed/MEDLINE/Cochrane Library and identified studies with I-III level of evidence using Oxford Centre for Evidence-Based Medicine recommendations.
View Article and Find Full Text PDFSuccessful Treatment of Palmoplantar Psoriasis With Apremilast in an Immunosuppressed Pediatric Patient on Concurrent Biologic Therapy.
Pediatr Dermatol
January 2025
Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
Immunosuppressive medication may be indicated in patients with severe psoriasis refractory to other treatment modalities. There is a subset of patients, however, who are immunosuppressed at baseline and are not ideal candidates for these agents. Here we report the case of a 15-year-old girl on immunosuppressive medication for preexisting pancolitis and chronic recurrent multifocal osteomyelitis who had an excellent response to concurrent apremilast therapy for her previously refractory palmoplantar psoriasis.
View Article and Find Full Text PDFImpact of disease manifestations on first biologic drug survival in axial spondyloarthritis: a real-life Canadian study.
Rheumatol Adv Pract
January 2025
Department of Medicine, Université de Montréal, Montreal, QC, Canada.
Objectives: The primary objective of this study was to assess the impact of extramusculoskeletal manifestations (EMMs) and peripheral musculoskeletal features on first biologic drug survival in subjects with axial spondyloarthritis (axSpA). The secondary objective was to evaluate the impact of reasons for treatment discontinuation.
Methods: A total of 593 axSpA patients from the SpondyloArthritis Research Consortium of Canada initiating a first biologic drug were identified between 2003 and 2023.
Methotrexate-Induced Accelerated Nodulosis: A Case Series.
Mediterr J Rheumatol
December 2024
Department of Clinical Immunology and Rheumatology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
Methotrexate-induced nodulosis, also known as methotrexate-induced accelerated nodulosis (MIAN), is a rare side effect of methotrexate therapy. Methotrexate (MTX) is commonly used to treat various autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In this case series, we present patients with MIAN, discussing their clinical features, diagnostic approaches, and management strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!